ClinicalTrials.gg
CompletedNCT07225647Updated Jan 14, 2026

A Study to Assess the Effect of Food on the Drug Levels of Admilparant

A Phase 1 interventional study of Admilparant in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of food on the drug levels of Admilparant

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a (BMI) of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening.
  • Participants must have a body weight of ≥ 50 kg for males and ≥ 45 kg for females at screening.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
  • Participants must not have had any previous exposure to Admilparant.
  • Participants must not have a history of any severe drug allergy or drug reaction (such as anaphylaxis or hepatotoxicity).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part 1: Treatment A

    Drug: Admilparant

  • Experimental
    Part 1: Treatment B

    Drug: Admilparant

  • Experimental
    Part 2: Treatment C

    Drug: Admilparant

  • Experimental
    Part 2: Treatment D

    Drug: Admilparant

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 13 days

  2. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to 13 days

  3. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to 13 days

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 13 days

  2. Terminal half-life (T-HALF)

    Time frame: Up to 13 days

  3. Apparent total body clearance (CLT/F)

    Time frame: Up to 13 days

  4. Apparent volume of distribution (Vz/F)

    Time frame: Up to 13 days

  5. Number of participants with adverse events (AEs)

    Time frame: Up to 13 days

  6. Number of participants with a change in clinical laboratory values

    Time frame: Up to 13 days

  7. Number of participants with a change in vital sign measurements

    Time frame: Up to 13 days

  8. Number of participants with a change in physical examination results

    Time frame: Up to 13 days

  9. Number of participants with a change in 12-lead electrocardiogram (ECG) results

    Time frame: Up to 13 days

07

Study locations

2 sites
  • Local Institution - 0002
    Lenexa, Kansas 66219-9746, United States
  • Local Institution - 0001
    Salt Lake City, Utah 84124-1365, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jan 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2025
First posted
Nov 10, 2025
StartActual
Nov 7, 2025
Primary completionActual
Jan 5, 2026
CompletionActual
Jan 5, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225647
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 7, 2025
Primary completion
Jan 5, 2026
Completion
Jan 5, 2026
Last update
Jan 14, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion